ijms-logo

Journal Browser

Journal Browser

Psoriasis: Molecular Research and Novel Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 292

Special Issue Editor


E-Mail Website
Guest Editor
Department of Dermatology, National Taiwan University, Taipei, Taiwan
Interests: psoriasis; immune mediated inflammatory skin diseases; cutaneous lymphoma; cosmetic dermatology

Special Issue Information

Dear Colleagues,

Psoriasis has pioneered advances in the use of biologics for its treatment for more than a decade in dermatology due to the better understanding of its pathogenesis. Biologics have become the gold standard in the treatment of moderate to severe psoriasis. However, there is also a recent trend for the use of novel oral agents, starting from apremilast and deucravacitinib to oral peptides targeting IL23 receptors and others.

The dichotomy of psoriasis and atopic dermatitis based on yin-yang theory has been replaced by more sophisticated immunologic mechanisms in recent years. Not only are immune cells involved but also other cells such as keratinocytes, fibroblasts, mast cells, and endothelial cells. Also, the discovery of IL36 receptor antagonist deficiency as the core cause of pustular psoriasis helps in our understanding of the many facets of psoriasis and its treatment.

For the treatment of psoriasis, which is a chronic disease in most cases, the potentials for better long-term control and even disease modification after treatment discontinuation have also come into the spotlight.

In this Special Issue of IJMS, submissions on “Psoriasis: Molecular Research and Novel Therapy" are welcome.

Prof. Dr. Tsen-Fang Tsai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • pathogenesis
  • treatment
  • biologics
  • novel therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 710 KiB  
Review
Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors
by Damiana Costin, Alexandra Maria Burlui, Anca Cardoneanu, Luana Andreea Macovei, Ciprian Rezus, Ioana Bratoiu, Patricia Richter, Ioana Ruxandra Mihai, Andreea Gherasim, Ciprian Danielescu and Elena Rezus
Int. J. Mol. Sci. 2024, 25(13), 7018; https://doi.org/10.3390/ijms25137018 - 27 Jun 2024
Viewed by 161
Abstract
TNF inhibitors (TNFi) have revolutionized the therapeutic management of various chronic immune-mediated inflammatory diseases. Despite their known benefits, these therapies are related to paradoxical adverse effects (PAEs), including paradoxical psoriasis (PP). Although the underlying mechanism remains somewhat unclear, some theories suggest that genetic [...] Read more.
TNF inhibitors (TNFi) have revolutionized the therapeutic management of various chronic immune-mediated inflammatory diseases. Despite their known benefits, these therapies are related to paradoxical adverse effects (PAEs), including paradoxical psoriasis (PP). Although the underlying mechanism remains somewhat unclear, some theories suggest that genetic factors, particularly certain single-nucleotide polymorphisms (SNPs), may play an important role. The present review aimed to research and analyze recent findings regarding the pathomechanisms involved in the appearance of PP and the association between various genetic factors and PP in individuals treated with TNFi. We performed a literature search and found that certain genes (IL23R, TNF, FBXL19, CTLA4, SLC12A8, TAP1) are strongly associated with the occurrence of PP in pediatric and adult patients during therapy with TNFi. The identification of the specific SNPs involved in the appearance of PP and other PAEs in patients treated with TNFi for various diseases and in different populations may later favor the recognition of those patients at a high risk of developing such adverse effects and could guide personalized therapeutic strategies in future years. Full article
(This article belongs to the Special Issue Psoriasis: Molecular Research and Novel Therapy)
Show Figures

Figure 1

Back to TopTop